How I do it – MRT-Diagnostik Hirntumor

Hinweis

Die Beiträge in der Rubrik „How I do it“ sind als Anregung und Orientierungshilfe zu verstehen. Es bleibt jeder/jedem Kollegin/Kollegen überlassen, von diesem Schema abzuweichen, sofern man sich mit der Indikationsfrage befasst hat und sachliche Gründe für ein alternatives Vorgehen sprechen.

• Literatur

• 1 Louis DN, Perry A, Reifenberger G. et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 2016; 131: 803-820
• 2 Johnson DR, Guerin JB, Giannini C. et al. 2016 Updates to the WHO Brain Tumor Classification System: What the Radiologist Needs to Know. RadioGraphics 2017; 37: 2164-2180
• 3 Wen PY, Chang SM, Van den Bent MJ. et al. Response Assessment in Neuro-Oncology Clinical Trials. J Clin Oncol 2017; 35: 2439-2449
• 4 Ellingson BM, Chung C, Pope WB. et al. Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape. J Neurooncol 2017; 134: 495-504
• 5 Ellingson BE, Benszus M, Boxerman J. et al. Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. Neuro-Oncology 2015. Im Internet: https://academic.oup.com/neuro-oncology/article/17/9/1188/1360348/Consensus-recommendations-for-a-standardized-Brain Stand: 28.05.2019
• 6 Delgado AF, Delgado AF. Discrimination between Glioma Grades II and III Using Dynamic Susceptibility Perfusion MRI: A Meta-Analysis. AJNR Am J Neuroradiol 2017; 38: 1348-1355
• 7 Senft C, Hattingen E, Pilatus U. et al. Diagnostic value of proton magnetic resonance spectroscopy in the noninvasive grading of solid gliomas: comparison of maximum and mean choline values. Neurosurgery 2009; 65: 908-913
• 8 Blasel S, Jurcoane A, Bähr O. et al. MR perfusion in and around the contrast-enhancement of primary CNS lymphomas. J Neurooncol 2013; 114: 127-134
• 9 Hattingen E, Good C, Weidauer S. et al. Brain surface reformatted images for fast and easy localization of perirolandic lesions. J Neurosurg 2005; 102: 302-310
• 10 Suh CH, Kim HS, Jung SC. et al. Multiparametric MRI as a potential surrogate endpoint for decision-making in early treatment response following concurrent chemoradiotherapy in patients with newly diagnosed glioblastoma: a systematic review and meta-analysis. Eur Radiol 2018; 28: 2628-2638
• 11 Blasel S, Zagorcic A, Jurcoane A. et al. Perfusion MRI in the Evaluation of Suspected Glioblastoma Recurrence: Perfusion MRI in Suspected Glioblastoma Recurrence. J Neuroimag 2016; 26: 116-123
• 12 Langen KJ, Galldiks N, Hattingen E. et al. Advances in neuro-oncology imaging. Nat Rev Neurol 2017; 13: 279-289